Citadel Advisors
BPMC

Citadel Advisors’s Blueprint Medicines BPMC Stock Holding History

Citadel Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-25,094
Closed -$3.22M – 12799
2025
Q2 		$3.22M Sell
25,094
-514
-2% -$53.4K ﹤0.01% 4865
2025
Q1 		$2.27M Sell
25,608
-624,350
-96% -$60.9M ﹤0.01% 5302
2024
Q4 		$56.7M Buy
649,958
+572,102
+735% +$52.4M 0.01% 1171
2024
Q3 		$7.2M Buy
77,856
+38,645
+99% +$3.84M ﹤0.01% 3386
2024
Q2 		$4.23M Buy
+39,211
New +$3.92M ﹤0.01% 4012
2024
Q1 		– Sell
-95,325
Closed -$8.18M – 14586
2023
Q4 		$8.79M Buy
95,325
+408
+0.4% +$26.4K ﹤0.01% 3019
2023
Q3 		$4.77M Sell
94,917
-16,062
-14% -$858K ﹤0.01% 3723
2023
Q2 		$7.01M Sell
110,979
-178,076
-62% -$9.68M ﹤0.01% 3150
2023
Q1 		$13M Buy
289,055
+65,633
+29% +$2.96M ﹤0.01% 2456
2022
Q4 		$9.79M Sell
223,422
-81,365
-27% -$3.9M ﹤0.01% 2875
2022
Q3 		$20.1M Buy
304,787
+235,528
+340% +$15.1M ﹤0.01% 1872
2022
Q2 		$3.5M Sell
69,259
-365,480
-84% -$21.4M ﹤0.01% 4474
2022
Q1 		$27.8M Buy
434,739
+338,425
+351% +$24.3M 0.01% 1626
2021
Q4 		$10.3M Buy
96,314
+92,741
+2,596% +$9.7M ﹤0.01% 3030
2021
Q3 		$367K Buy
3,573
+980
+38% +$91.3K ﹤0.01% 10599
2021
Q2 		$228K Buy
+2,593
New +$238K ﹤0.01% 11876
2021
Q1 		– Sell
-21,603
Closed -$2.16M – 13167
2020
Q4 		$2.42M Sell
21,603
-48,188
-69% -$5.08M ﹤0.01% 4956
2020
Q3 		$6.47M Sell
69,791
-354,819
-84% -$27.3M ﹤0.01% 2805
2020
Q2 		$33.1M Sell
424,610
-21,457
-5% -$1.45M 0.01% 1084
2020
Q1 		$26.1M Buy
446,067
+384,208
+621% +$24.7M 0.01% 1032
2019
Q4 		$4.96M Sell
61,859
-15,684
-20% -$1.17M ﹤0.01% 3088
2019
Q3 		$5.7M Buy
77,543
+14,879
+24% +$1.29M ﹤0.01% 2929
2019
Q2 		$5.91M Sell
62,664
-18,326
-23% -$1.51M ﹤0.01% 2859
2019
Q1 		$6.48M Buy
80,990
+64,201
+382% +$4.74M ﹤0.01% 2626
2018
Q4 		$905K Sell
16,789
-201,720
-92% -$12.3M ﹤0.01% 5453
2018
Q3 		$17.1M Buy
218,509
+173,614
+387% +$12.1M 0.01% 1542
2018
Q2 		$2.85M Buy
44,895
+36,779
+453% +$2.93M ﹤0.01% 3560
2018
Q1 		$744K Sell
8,116
-10,142
-56% -$874K ﹤0.01% 5244
2017
Q4 		$1.38M Buy
+18,258
New +$1.28M ﹤0.01% 4160
2017
Q3 		– Sell
-290,782
Closed -$15.5M – 7534
2017
Q2 		$14.7M Buy
290,782
+119,208
+69% +$5.06M 0.01% 1186
2017
Q1 		$6.86M Buy
171,574
+96,863
+130% +$3.47M 0.01% 1734
2016
Q4 		$2.1M Buy
74,711
+56,061
+301% +$1.69M ﹤0.01% 2900
2016
Q3 		$554K Buy
+18,650
New +$463K ﹤0.01% 4701
2016
Q1 		– Sell
-137,303
Closed -$3.62M – 6817
2015
Q4 		$3.62M Sell
137,303
-409,688
-75% -$9.22M ﹤0.01% 2124
2015
Q3 		$11.7M Sell
546,991
-136,593
-20% -$3.78M 0.01% 1243
2015
Q2 		$18.1M Buy
+683,584
New +$19.5M 0.02% 1062

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citadel Advisors's BPMC Position: Q3 2025 in Review

Citadel Advisors sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 25,094 shares — an estimated $3.22M sold.

Citadel Advisors first reported a position in BPMC in Q2 2015 and held it in 36 quarters. The position peaked at $56.7M in Q4 2024. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Citadel Advisors reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 25,094 Blueprint Medicines shares in Q3 2025, an estimated $3.22M.
  • Citadel Advisors first reported a position in Blueprint Medicines in Q2 2015 and held it in 36 quarters.
  • Citadel Advisors's Blueprint Medicines position peaked at $56.7M in Q4 2024.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.